Essex Woodlands Management, Inc. Activity Q4 2011-Q3 2023

Add to watchlist

Q3 2023

			Value		Shares		↓ Weighting
EYPT	Sell	EYEPOINT PHARMACEUTICALS INC	$27,892,459	-23.5%	3,490,921	-16.7%	24.59%	-10.9%
VERO	Buy	VENUS CONCEPT, INC.	$2,134,822	-6.7%	1,089,195	+0.0%	1.88%	+8.7%

Q2 2023

			Value		Shares		↓ Weighting
TELA	New	TELA BIO, INC.	$41,641,482	–	4,110,709	–	31.52%	–
BVS	New	BIOVENTUS	$37,631,626	–	13,021,324	–	28.48%	–
EYPT	New	EYEPOINT PHARMACEUTICALS INC	$36,461,013	–	4,190,921	–	27.59%	–
RVNC	New	REVANCE THERAPEUTICS INC	$11,568,821	–	457,085	–	8.76%	–
MNOV	New	MEDICINOVA INC	$2,543,664	–	1,105,941	–	1.92%	–
VERO	New	VENUS CONCEPT, INC.	$2,287,299	–	1,089,190	–	1.73%	–

Q4 2022

			Value		Shares		↓ Weighting
MNOV	Exit	MEDICINOVA INC	$0	–	-1,105,941	–	-0.99%	–
VERO	Exit	VENUS CONCEPT, INC.	$0	–	-21,169,457	–	-2.97%	–
RVNC	Exit	REVANCE THERAPEUTICS INC	$0	–	-457,085	–	-5.10%	–
EYPT	Exit	EYEPOINT PHARMACEUTICALS INC	$0	–	-4,190,921	–	-13.70%	–
TELA	Exit	TELA BIO, INC.	$0	–	-4,110,709	–	-14.47%	–
MDXG	Exit	MIMEDX GROUP, INC.	$0	–	-23,415,584	–	-27.77%	–
BVS	Exit	BIOVENTUS	$0	–	-12,096,702	–	-34.99%	–

Q3 2022

			Value		Shares		↓ Weighting
TELA	Buy	TELA BIO, INC.	$35,023,000	+40.1%	4,110,709	+15.3%	14.47%	+40.1%
CBIO	Exit	CATALYST BIOSCIENCES INC	$0	–	-78,622	–	-0.06%	–
	Exit	SONENDO INC	$0	–	-1,992,526	–	-1.42%	–

Q2 2022

			Value		Shares		↓ Weighting
BVS	New	BIOVENTUS	$82,500,000	–	12,096,702	–	34.10%	–
MDXG	New	MIMEDX GROUP, INC.	$81,252,000	–	23,415,584	–	33.58%	–
EYPT	New	EYEPOINT PHARMACEUTICALS INC	$32,983,000	–	4,190,921	–	13.63%	–
TELA	New	TELA BIO, INC.	$24,996,000	–	3,565,709	–	10.33%	–
VERO	New	VENUS CONCEPT, INC.	$7,515,000	–	21,169,457	–	3.11%	–
RVNC	New	REVANCE THERAPEUTICS INC	$6,317,000	–	457,085	–	2.61%	–
	New	SONENDO INC	$3,427,000	–	1,992,526	–	1.42%	–
MNOV	New	MEDICINOVA INC	$2,798,000	–	1,105,941	–	1.16%	–
CBIO	New	CATALYST BIOSCIENCES INC	$140,000	–	78,622	–	0.06%	–

Q4 2021

			Value		Shares		↓ Weighting
CBIO	Exit	CATALYST BIOSCIENCES INC	$0	–	-78,622	–	-0.07%	–
MNOV	Exit	MEDICINOVA INC	$0	–	-1,105,941	–	-0.93%	–
RVNC	Exit	REVANCE THERAPEUTICS INC	$0	–	-472,590	–	-2.92%	–
AXGN	Exit	AXOGEN INC	$0	–	-1,276,645	–	-4.48%	–
TELA	Exit	TELA BIO, INC.	$0	–	-1,833,989	–	-5.56%	–
VERO	Exit	VENUS CONCEPT, INC.	$0	–	-12,417,856	–	-6.92%	–
EYPT	Exit	EYEPOINT PHARMACEUTICALS INC	$0	–	-4,190,921	–	-9.69%	–
MDXG	Exit	MIMEDX GROUP, INC.	$0	–	-23,376,623	–	-31.43%	–
BVS	Exit	BIOVENTUS	$0	–	-12,096,702	–	-38.01%	–

Q3 2021

			Value		Shares		↓ Weighting
TELA	Buy	TELA BIO, INC.	$25,052,000	-1.6%	1,833,989	+16.1%	5.56%	+47.8%
RVNC	Sell	REVANCE THERAPEUTICS INC	$13,166,000	-64.7%	472,590	-64.6%	2.92%	-46.9%

Q2 2021

			Value		Shares		↓ Weighting
MDXG	New	MIMEDX GROUP, INC.	$292,442,000	–	23,376,623	–	43.20%	–
BVS	New	BIOVENTUS	$212,902,000	–	12,096,702	–	31.45%	–
VERO	New	VENUS CONCEPT, INC.	$38,620,000	–	12,417,856	–	5.70%	–
EYPT	New	EYEPOINT PHARMACEUTICALS INC	$37,676,000	–	4,190,921	–	5.56%	–
RVNC	New	REVANCE THERAPEUTICS INC	$37,277,000	–	1,333,692	–	5.51%	–
AXGN	New	AXOGEN INC	$27,588,000	–	1,276,645	–	4.08%	–
TELA	New	TELA BIO, INC.	$25,455,000	–	1,580,089	–	3.76%	–
MNOV	New	MEDICINOVA INC	$4,700,000	–	1,105,941	–	0.69%	–
CBIO	New	CATALYST BIOSCIENCES INC	$340,000	–	78,622	–	0.05%	–

Q4 2020

			Value		Shares		↓ Weighting
ELGXQ	Exit	ENDOLOGIX INC	$0	–	-125,747	–	-0.00%	–
CBIO	Exit	CATALYST BIOSCIENCES INC	$0	–	-78,622	–	-0.18%	–
MNOV	Exit	MEDICINOVA INC	$0	–	-1,105,941	–	-3.08%	–
EYPT	Exit	EYEPOINT PHARMACEUTICALS INC	$0	–	-41,909,219	–	-11.58%	–
AXGN	Exit	AXOGEN INC	$0	–	-1,981,888	–	-12.25%	–
TELA	Exit	TELA BIO, INC.	$0	–	-1,475,293	–	-12.96%	–
VERO	Exit	VENUS CONCEPT, INC.	$0	–	-12,417,856	–	-15.31%	–
RVNC	Exit	REVANCE THERAPEUTICS INC	$0	–	-3,342,047	–	-44.64%	–

Q3 2020

			Value		Shares		↓ Weighting
TELA	Buy	TELA BIO, INC.	$24,401,000	+35.3%	1,475,293	+6.0%	12.96%	+46.5%
AXGN	Sell	AXOGEN INC	$23,049,000	+2.7%	1,981,888	-18.4%	12.25%	+11.2%

Q2 2020

			Value		Shares		↓ Weighting
RVNC	New	REVANCE THERAPEUTICS INC	$81,613,000	–	3,342,047	–	40.04%	–
VERO	New	VENUS CONCEPT, INC.	$43,338,000	–	12,417,856	–	21.26%	–
EYPT	New	EYEPOINT PHARMACEUTICALS INC	$31,851,000	–	41,909,219	–	15.62%	–
AXGN	New	AXOGEN INC	$22,453,000	–	2,429,999	–	11.02%	–
TELA	New	TELA BIO, INC.	$18,037,000	–	1,391,768	–	8.85%	–
MNOV	New	MEDICINOVA INC	$5,994,000	–	1,105,941	–	2.94%	–
CBIO	New	CATALYST BIOSCIENCES INC	$462,000	–	78,622	–	0.23%	–
ELGXQ	New	ENDOLOGIX INC	$101,000	–	125,747	–	0.05%	–

Q4 2019

			Value		Shares		↓ Weighting
CBIO	Exit	CATALYST BIOSCIENCES INC	$0	–	-78,622	–	-0.24%	–
ELGXQ	Exit	ENDOLOGIX INC	$0	–	-125,747	–	-0.62%	–
MNOV	Exit	MEDICINOVA INC	$0	–	-1,170,370	–	-5.94%	–
AXGN	Exit	AXOGEN INC	$0	–	-2,429,999	–	-18.89%	–
RVNC	Exit	REVANCE THERAPEUTICS INC	$0	–	-3,342,047	–	-27.06%	–
EYPT	Exit	EYEPOINT PHARMACEUTICALS INC	$0	–	-41,909,219	–	-47.25%	–

Q2 2019

			Value		Shares		↓ Weighting
EYPT	New	EYEPOINT PHARMACEUTICALS INC	$68,731,000	–	41,909,219	–	39.63%	–
AXGN	New	AXOGEN INC	$48,114,000	–	2,429,999	–	27.74%	–
RVNC	New	REVANCE THERAPEUTICS INC	$43,346,000	–	3,342,047	–	24.99%	–
MNOV	New	MEDICINOVA INC	$11,271,000	–	1,170,370	–	6.50%	–
ELGXQ	New	ENDOLOGIX INC	$1,390,000	–	125,747	–	0.80%	–
CBIO	New	CATALYST BIOSCIENCES INC	$579,000	–	78,622	–	0.33%	–

Q4 2018

			Value		Shares		↓ Weighting
ACUR	Exit	ACURA PHARMACEUTICALS INC	$0	–	-1,956,397	–	-0.08%	–
CBIO	Exit	CATALYST	$0	–	-78,622	–	-0.18%	–
ELGX	Exit	ENDOLOGIX INC	$0	–	-1,257,468	–	-1.39%	–
MNOV	Exit	MEDICINOVA INC	$0	–	-1,170,370	–	-3.04%	–
RVNC	Exit	REVANCE THERAPEUTICS INC	$0	–	-3,342,047	–	-17.27%	–
CORI	Exit	CORIUM	$0	–	-9,353,304	–	-18.50%	–
AXGN	Exit	AXOGEN INC	$0	–	-3,711,111	–	-28.44%	–
PSDV	Exit	EYEPOINT	$0	–	-41,903,956	–	-31.11%	–

Q3 2018

			Value		Shares		↓ Weighting
PSDV	Buy	EYEPOINT	$149,597,000	+182.4%	41,903,956	+64.5%	31.11%	+152.9%

Q2 2018

			Value		Shares		↓ Weighting
AXGN	New	AXOGEN INC	$186,483,000	–	3,711,111	–	43.30%	–
RVNC	New	REVANCE THERAPEUTICS INC	$91,739,000	–	3,342,047	–	21.30%	–
CORI	New	CORIUM	$74,920,000	–	9,353,304	–	17.40%	–
PSDV	New	EYEPOINT	$52,978,000	–	25,470,390	–	12.30%	–
ELGX	New	ENDOLOGIX INC	$13,623,000	–	1,257,468	–	3.16%	–
MNOV	New	MEDICINOVA INC	$9,316,000	–	1,170,370	–	2.16%	–
CBIO	New	CATALYST	$933,000	–	78,622	–	0.22%	–
ACUR	New	ACURA PHARMACEUTICALS INC	$704,000	–	1,956,397	–	0.16%	–

Q4 2017

			Value		Shares		↓ Weighting
CBIO	Exit	CATALYST	$0	–	-78,622	–	-0.07%	–
ACUR	Exit	ACURA PHARMACEUTICALS INC	$0	–	-1,956,397	–	-0.16%	–
MNOV	Exit	MEDICINOVA INC	$0	–	-1,170,370	–	-1.32%	–
ELGX	Exit	ENDOLOGIX INC	$0	–	-1,257,468	–	-2.02%	–
ENTL	Exit	ENTELLUS MEDICAL INC	$0	–	-3,231,656	–	-10.58%	–
AXGN	Exit	AXOGEN INC	$0	–	-4,861,111	–	-16.69%	–
CORI	Exit	CORIUM	$0	–	-9,353,304	–	-18.39%	–
RVNC	Exit	REVANCE THERAPEUTICS INC	$0	–	-4,592,047	–	-22.44%	–
ABMD	Exit	ABIOMED INC	$0	–	-946,818	–	-28.32%	–

Q3 2017

			Value		Shares		↓ Weighting
ABMD	Sell	ABIOMED INC	$159,634,000	-23.2%	946,818	-34.7%	28.32%	-24.6%

Q2 2017

			Value		Shares		↓ Weighting
ABMD	New	ABIOMED INC	$207,785,000	–	1,450,000	–	37.57%	–
RVNC	New	REVANCE THERAPEUTICS INC	$121,230,000	–	4,592,047	–	21.92%	–
AXGN	New	AXOGEN INC	$81,424,000	–	4,861,111	–	14.72%	–
CORI	New	CORIUM	$69,776,000	–	9,353,304	–	12.62%	–
ENTL	New	ENTELLUS MEDICAL INC	$53,516,000	–	3,231,656	–	9.68%	–
ELGX	New	ENDOLOGIX INC	$11,699,000	–	1,257,468	–	2.12%	–
MNOV	New	MEDICINOVA INC	$6,156,000	–	1,170,370	–	1.11%	–
ACUR	New	ACURA PHARMACEUTICALS INC	$1,096,000	–	1,956,397	–	0.20%	–
CBIO	New	CATALYST	$372,000	–	78,622	–	0.07%	–

Q4 2016

			Value		Shares		↓ Weighting
CBIO	Exit	CATALYST BIOSCIENCES INC	$0	–	-1,179,352	–	-0.30%	–
LGND	Exit	LIGAND PHARMACEUTICALS INC	$0	–	-32,893	–	-0.50%	–
ACUR	Exit	ACURA PHARMACEUTICALS INC	$0	–	-1,956,397	–	-0.65%	–
MNOV	Exit	MEDICINOVA INC	$0	–	-1,170,370	–	-1.82%	–
ELGX	Exit	ENDOLOGIX INC	$0	–	-1,257,468	–	-4.76%	–
AXGN	Exit	AXOGEN INC	$0	–	-4,861,111	–	-9.13%	–
CORI	Exit	CORIUM INTL INC	$0	–	-9,353,304	–	-10.96%	–
RVNC	Exit	REVANCE THERAPEUTICS INC	$0	–	-4,592,047	–	-15.49%	–
ENTL	Exit	ENTELLUS MED INC	$0	–	-3,813,197	–	-17.60%	–
ABMD	Exit	ABIOMED INC	$0	–	-1,450,000	–	-38.79%	–

Q2 2016

			Value		Shares		↓ Weighting
ABMD	New	ABIOMED INC	$158,471,000	–	1,450,000	–	39.93%	–
ENTL	New	ENTELLUS MED INC	$69,667,000	–	3,813,197	–	17.55%	–
RVNC	New	REVANCE THERAPEUTICS INC	$62,452,000	–	4,592,047	–	15.74%	–
AXGN	New	AXOGEN INC	$33,444,000	–	4,861,111	–	8.43%	–
CORI	New	CORIUM INTL INC	$32,456,000	–	9,353,304	–	8.18%	–
ELGX	New	ENDOLOGIX INC	$22,174,000	–	1,257,468	–	5.59%	–
MNOV	New	MEDICINOVA INC	$8,836,000	–	1,170,370	–	2.23%	–
LGND	New	LIGAND PHARMACEUTICALS INC	$3,923,000	–	32,893	–	0.99%	–
ACUR	New	ACURA PHARMACEUTICALS INC	$3,619,000	–	1,956,397	–	0.91%	–
CBIO	New	CATALYST BIOSCIENCES INC	$1,824,000	–	1,179,352	–	0.46%	–

Q4 2015

			Value		Shares		↓ Weighting
MNOV	Exit	MEDICINOVA INC	$0	–	-1,170,370	–	-0.60%	–
ACUR	Exit	ACURA PHARMACEUTICALS INC	$0	–	-1,956,397	–	-0.84%	–
CBIO	Exit	CATALYST BIOSCIENCES INC	$0	–	-1,179,352	–	-1.03%	–
AXGN	Exit	AXOGEN INC	$0	–	-4,861,111	–	-3.66%	–
ELGX	Exit	ENDOLOGIX INC	$0	–	-1,257,468	–	-3.88%	–
ENTL	Exit	ENTELLUS MED INC	$0	–	-3,813,197	–	-12.56%	–
CORI	Exit	CORIUM INTL INC	$0	–	-9,353,304	–	-15.99%	–
RVNC	Exit	REVANCE THERAPEUTICS INC	$0	–	-4,592,047	–	-24.98%	–
ABMD	Exit	ABIOMED INC	$0	–	-2,150,000	–	-36.46%	–

Q3 2015

			Value		Shares		↓ Weighting
AXGN	New	AXOGEN INC	$20,028,000	–	4,861,111	–	3.66%	–
CBIO	New	CATALYST BIOSCIENCES INC	$5,658,000	–	1,179,352	–	1.03%	–
ACUR	New	ACURA PHARMACEUTICALS INC	$4,598,000	–	1,956,397	–	0.84%	–
ACUR	Exit	ACURA PHARMACEUTICALS INC	$0	–	-9,871,985	–	-1.75%	–

Q2 2015

			Value		Shares		↓ Weighting
RVNC	New	REVANCE THERAPEUTICS INC	$146,854,000	–	4,592,047	–	26.51%	–
ABMD	New	ABIOMED INC	$141,319,000	–	2,150,000	–	25.51%	–
CORI	New	CORIUM INTL INC	$128,047,000	–	9,353,304	–	23.11%	–
ENTL	New	ENTELLUS MED INC	$98,647,000	–	3,813,197	–	17.80%	–
ELGX	New	ENDOLOGIX INC	$24,875,000	–	1,257,468	–	4.49%	–
ACUR	New	ACURA PHARMACEUTICALS INC	$9,684,000	–	9,871,985	–	1.75%	–
MNOV	New	MEDICINOVA INC	$4,623,000	–	1,170,370	–	0.83%	–

Q4 2014

			Value		Shares		↓ Weighting
ECTE	Exit	ECHO THERAPEUTICS INC	$0	–	-12,319	–	-0.00%	–
PTN	Exit	PALATIN TECHNOLOGIES INC	$0	–	-23,928	–	-0.01%	–
CRIS	Exit	CURIS INC	$0	–	-233,797	–	-0.12%	–
MNOV	Exit	MEDICINOVA INC	$0	–	-1,170,370	–	-1.27%	–
ZIOP	Exit	ZIOPHARM ONCOLOGY INC	$0	–	-2,764,908	–	-2.60%	–
ACUR	Exit	ACURA PHARMACEUTICALS INC	$0	–	-10,284,886	–	-2.78%	–
ELGX	Exit	ENDOLOGIX INC	$0	–	-2,514,936	–	-11.52%	–
CORI	Exit	CORIUM INTL INC	$0	–	-9,353,304	–	-20.91%	–
ABMD	Exit	ABIOMED INC	$0	–	-3,150,000	–	-28.48%	–
RVNC	Exit	REVANCE THERAPEUTICS INC	$0	–	-4,592,047	–	-32.32%	–

Q3 2014

			Value		Shares		↓ Weighting
ELGX	Sell	ENDOLOGIX INC	$31,644,000	-47.3%	2,514,936	-10.7%	11.52%	-7.8%
HZNP	Exit	HORIZON PHARMA INC	$0	–	-5,815,940	–	-18.51%	–

Q2 2014

			Value		Shares		↓ Weighting
RVNC	New	REVANCE THERAPEUTICS INC	$156,130,000	–	4,592,047	–	32.47%	–
HZNP	New	HORIZON PHARMA INC	$88,982,000	–	5,815,940	–	18.51%	–
ABMD	New	ABIOMED INC	$79,191,000	–	3,150,000	–	16.47%	–
CORI	New	CORIUM INTL INC	$72,675,000	–	9,353,304	–	15.12%	–
ELGX	New	ENDOLOGIX INC	$60,066,000	–	2,814,936	–	12.49%	–
ACUR	New	ACURA PHARMACEUTICALS INC	$10,662,000	–	10,284,886	–	2.22%	–
ZIOP	New	ZIOPHARM ONCOLOGY INC	$10,257,000	–	2,764,908	–	2.13%	–
MNOV	New	MEDICINOVA INC	$2,376,000	–	1,170,370	–	0.49%	–
CRIS	New	CURIS INC	$435,000	–	233,797	–	0.09%	–
ECTE	New	ECHO THERAPEUTICS INC	$28,000	–	12,319	–	0.01%	–
PTN	New	PALATIN TECHNOLOGIES INC	$24,000	–	23,928	–	0.01%	–

Q4 2013

			Value		Shares		↓ Weighting
PTN	Exit	PALATIN TECHNOLOGIES INC	$0	–	-23,928	–	-0.01%	–
ECTE	Exit	ECHO THERAPEUTICS INC	$0	–	-12,319	–	-0.02%	–
CRIS	Exit	CURIS INC	$0	–	-233,797	–	-0.69%	–
SLTM	Exit	SOLTA MED INC	$0	–	-1,330,219	–	-1.82%	–
MNOV	Exit	MEDICINOVA INC	$0	–	-1,170,370	–	-1.99%	–
CO	Exit	CHINA CORD BLOOD CORP	$0	–	-1,037,690	–	-2.60%	–
ZIOP	Exit	ZIOPHARM ONCOLOGY INC	$0	–	-2,764,908	–	-6.42%	–
HZNP	Exit	HORIZON PHARMA INC	$0	–	-5,815,940	–	-11.89%	–
ACUR	Exit	ACURA PHARMACEUTICALS INC	$0	–	-10,294,886	–	-12.44%	–
ELGX	Exit	ENDOLOGIX INC	$0	–	-1,165,428	–	-22.47%	–
ABMD	Exit	ABIOMED INC	$0	–	-3,150,000	–	-39.64%	–

Q2 2013

			Value		Shares		↓ Weighting
ABMD	New	ABIOMED INC	$67,914,000	–	3,150,000	–	52.05%	–
ACUR	New	ACURA PHARMACEUTICALS INC	$18,713,000	–	10,294,886	–	14.34%	–
ELGX	New	ENDOLOGIX INC	$15,477,000	–	1,165,428	–	11.86%	–
HZNP	New	HORIZON PHARMA INC	$13,139,000	–	5,815,940	–	10.07%	–
ZIOP	New	ZIOPHARM ONCOLOGY INC	$5,414,000	–	2,764,908	–	4.15%	–
MNOV	New	MEDICINOVA INC	$3,078,000	–	1,170,370	–	2.36%	–
SLTM	New	SOLTA MED INC	$3,033,000	–	1,330,219	–	2.32%	–
CO	New	CHINA CORD BLOOD CORP	$2,915,000	–	1,037,690	–	2.23%	–
CRIS	New	CURIS INC	$745,000	–	233,797	–	0.57%	–
ECTE	New	ECHO THERAPEUTICS INC	$31,000	–	12,319	–	0.02%	–
PTN	New	PALATIN TECHNOLOGIES INC	$14,000	–	23,928	–	0.01%	–

Compare quarters

Export Essex Woodlands Management, Inc.'s holdings